TimothyK.HuyckMD

Oncology • Papillion, NE

Physician

Join to view full profile

Dr. Huyck is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Huyck's full profile

Already have an account?

Office
611 Fenwick Dr
Papillion, NE 68046
Phone+1 402-593-3141

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2009 - 2012
Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 2005 - 2009
Creighton University School of MedicineClass of 2005

Certifications & Licensure

IA State Medical License 2022 - 2026
NE State Medical License 2006 - 2026
IL State Medical License 2009 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Start of enrollment: 2010 Jan 18
Completed
Phase 2
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2018 Oct 26
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer Start of enrollment: 2020 Jun 17
Recruiting
Phase 2, Phase 3
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Start of enrollment: 2020 Jul 01
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
Erkut H Borazanci, Nathan Bahary, Vincent Chung, Timothy K Huyck, Ebenezer A Kio
The Oncologist. 2024-11-04
3 citations
Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).
Walid L Shaib, Rupji Manali, Yuan Liu, Bassel El-Rayes, Patrick Loehrer
European Journal of Cancer. 2023-08-01
28 citations
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase ...
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, Tim Larson, Allen L Cohn
Eclinicalmedicine. 2023-04-01